Department of Orthopaedics, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huaian, Jiangsu, China.
Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1428-1433. doi: 10.26355/eurrev_201902_17099.
Our study aimed to evaluate the expression pattern and prognostic value of long noncoding RNA HAGLROS (HAGLROS) in osteosarcoma.
qRT-PCR was performed to detect the expression levels of HAGLROS in osteosarcoma tissues and matched normal bone tissues. The relationship between the expression of HAGLROS and the clinicopathological features was analyzed by chi-square test. The survival curves were calculated by the Kaplan-Meier method and the difference by the log-rank test. The Cox proportional hazards model for multivariate survival analysis was used to assess predictors related to survival.
Herein, we showed that HAGLROS was frequently upregulated in osteosarcoma tissue and cell lines compared to normal human bone tissues (p < 0.01). In addition, HAGLROS upregulation more frequently occurred in osteosarcoma specimens with advanced TNM stage (p = 0.023), positively distant metastasis (p = 0.002) and poor differentiation (p = 0.021). Survival analysis showed that osteosarcoma patients with higher HAGLROS expression suffered poorer overall survival (p = 0.012) and disease-free survival (p = 0.003). In a multivariate Cox model, it was confirmed that HAGLROS up-regulation was an independent poor prognostic factor for both 5-year overall survival (HR=3.546, 95% CI: 1.273-5.326; p = 0.002) and 5-year disease-free survival (HR=3.854, 95% CI: 1.427-5.885; p = 0.001).
We showed that HAGLROS was an independent predictor of unfavorable prognosis in osteosarcoma patients and may serve as a potential target.
本研究旨在评估长链非编码 RNA HAGLROS（HAGLROS）在骨肉瘤中的表达模式和预后价值。
采用 qRT-PCR 检测骨肉瘤组织和配对正常骨组织中 HAGLROS 的表达水平。采用卡方检验分析 HAGLROS 表达与临床病理特征的关系。采用 Kaplan-Meier 法计算生存曲线，对数秩检验比较差异。采用 Cox 比例风险模型进行多因素生存分析，评估与生存相关的预测因素。
本研究表明，与正常人骨组织相比，HAGLROS 在骨肉瘤组织和细胞系中频繁上调（p < 0.01）。此外，HAGLROS 上调更频繁地发生在具有晚期 TNM 分期（p = 0.023）、阳性远处转移（p = 0.002）和低分化（p = 0.021）的骨肉瘤标本中。生存分析显示，HAGLROS 表达较高的骨肉瘤患者总生存（p = 0.012）和无病生存（p = 0.003）较差。在多因素 Cox 模型中，证实 HAGLROS 上调是 5 年总生存（HR=3.546，95%CI：1.273-5.326；p = 0.002）和 5 年无病生存（HR=3.854，95%CI：1.427-5.885；p = 0.001）的独立不良预后因素。
我们表明，HAGLROS 是骨肉瘤患者不良预后的独立预测因子，可能成为潜在的治疗靶点。
